Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
暂无分享,去创建一个
Ulrik B Nielsen | U. Nielsen | C. Benz | John W. Park | J. Marks | D. Kirpotin | K. Hong | Y. Shao | James D Marks | Keelung Hong | John W Park | Dmitri B Kirpotin | Yi Shao | Christopher C Benz | Edward M Pickering | M Refaat Shalaby | E. Pickering | M. Refaat Shalaby
[1] E. Moase,et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.
[2] A. Gabizon,et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Marks,et al. Toward selection of internalizing antibodies from phage libraries. , 1999, Biochemical and biophysical research communications.
[4] F. Martin,et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.
[5] L. Björck,et al. On the interaction between single chain Fv antibodies and bacterial immunoglobulin-binding proteins. , 1994, Journal of immunological methods.
[6] G. Scott,et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells , 1993, Molecular and cellular biology.
[7] U. Nielsen,et al. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. , 2000, Cancer research.
[8] F. Révillion,et al. ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.
[9] R. Neve,et al. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. , 2001, Biochemical and biophysical research communications.
[10] C. Benz,et al. Anti-HER2 immunoliposomes for targeted therapy of human tumors. , 1997, Cancer letters.
[11] R. Karlsson,et al. Analysis of active antibody concentration. Separation of affinity and concentration parameters. , 1993, Journal of immunological methods.
[12] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[13] Y. Barenholz,et al. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. , 1992, Biochimica et biophysica acta.
[14] M S Newman,et al. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. , 1997, Biochimica et biophysica acta.
[15] U. Nielsen,et al. Selection of tumor-specific internalizing human antibodies from phage libraries. , 2000, Journal of molecular biology.
[16] F. Martin,et al. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. , 1993, Cancer research.
[17] H R Hoogenboom,et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. , 1991, Journal of molecular biology.
[18] J. Huston,et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. , 1995, Immunotechnology : an international journal of immunological engineering.
[19] J. Philippot,et al. The influence of coupling transferrin to liposomes or minibeads on its uptake and fate in leukemic L2C cells , 1987, FEBS letters.
[20] D. Papahadjopoulos,et al. Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. , 1990, Biochimica et biophysica acta.
[21] D. Papahadjopoulos,et al. Endocytosis and intracellular fate of liposomes using pyranine as a probe. , 1990, Biochemistry.
[22] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[23] Y. Yarden,et al. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[24] E. Vitetta,et al. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. , 1988, Journal of immunology.
[25] T. Ishida,et al. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs , 1999, FEBS letters.
[26] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] John W. Park,et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[28] B. Groner,et al. Targeted therapy of Schwannoma cells in immunocompetent rats with an erbB2‐specific antibody‐toxin , 1997, International journal of cancer.
[29] C. Cornelisse,et al. Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer. , 1995, British Journal of Cancer.
[30] W. Wels,et al. Target Cell-specific DNA Transfer Mediated by a Chimeric Multidomain Protein , 1996, The Journal of Biological Chemistry.
[31] Brad Snedecor,et al. High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment , 1992, Bio/Technology.
[32] L. Leserman,et al. Drug transfer into lymphoblasts mediated by liposomes bound to distinct sites on H-2 encoded I-A, I-E, and K molecules. , 1982, Journal of immunology.
[33] K. Matthay,et al. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. , 1989, Cancer research.
[34] Y. Yarden,et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.
[35] Yinhua Yu,et al. Antibody‐induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c‐erbb‐2 (her‐2/neu) gene product p185 , 1993, International journal of cancer.
[36] W. R. Morrison. A FAST, SIMPLE AND RELIABLE METHOD FOR THE MICRODETERMINATION OF PHOSPHORUS IN BIOLOGICAL MATERIALS. , 1964, Analytical biochemistry.
[37] Y. Yarden,et al. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[38] G. Adams,et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. , 1996, Journal of molecular biology.
[39] Marks,et al. Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. , 2000, Pharmaceutical science & technology today.
[40] John W. Park,et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.
[41] J. Gerhart,et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[42] L. Kuhn,et al. The role of structure in antibody cross-reactivity between peptides and folded proteins. , 1998, Journal of molecular biology.
[43] I. Ahmad,et al. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. , 1995, Biochemical Society transactions.
[44] B. Sikic,et al. Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition. , 1987, Cancer research.
[45] H. Gibbs,et al. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? , 1999, Seminars in oncology.
[46] L. Huang,et al. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. , 1995, Biochimica et biophysica acta.
[47] D. Lasič,et al. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes , 1992, International journal of cancer.